Reduction of an arteriosclerotic lesion by selective absorption of electromagnetic energy in a component thereof

• US 5,876,397 A
• Filed: 09/29/1992
• Issued: 03/02/1999
• Est. Priority Date: 01/24/1984
• Status: Expired due to Term

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Corporation
• Inventors: Edelman, William, Constantinou, Dennis, Rosenbluth, Robert F.
• Primary Examiner(s): COHEN, LEE S
• Application Number:
  US07/953,329
• Time in Patent Office: 2,345 Days
• Field of Search: 606/3, 606/7, 606/15
• US Class Current: 606/3
• CPC Class Codes: A61B 18/245 for removing obstructions in blood vessels or calculi
• CPC Class Codes: A61B 18/28 for heating a thermal probe or absorber
• CPC Class Codes: A61B 2018/2261 with scattering, diffusion or dispersion of light

Abstract

A novel method for reducing an arteriosclerotic lesion is disclosed in which the electromagnetic energy directed at the lesion is selectively absorbed by a lesion component, e.g. cholesterol. The resulting decomposition of said lesion component leads to reduction of the lesion with minimal risk of damage to blood constituents and adjacent healthy blood vessel tissue. Preferably, monochromatic electromagnetic energy is generated by a laser and is conducted to the vicinity of the lesion by at least one optical fiber.

Claims

1. A method for reducing an arteriosclerotic lesion in a blood vessel of a patient which comprises directing sufficient electromagnetic energy at said lesion to reduce it, with essentially all of said electromagnetic energy directed at said lesion being of a wavelength in the ultraviolet region at which energy is selectively absorbed, as compared to absorption by whole blood and non-arteriosclerotic blood vessel tissue, by a lesion component present in said lesion at a greater weight percentage (dry basis) than in the whole blood or surrounding non-arteriosclerotic blood vessel tissue of the patient.

2. The method of claim 1 wherein said wavelength is from about 200 nanometers to about 300 nanometers.

3. The method of claim 1 wherein said lesion component is present in said lesion at no less than about 1 percent of the total weight of said lesion on a dry basis.

4. The method of claim 3 wherein said lesion component is present in said lesion at no less than about 5 percent of the total weight of said lesion on a dry basis.

5. The method of claim 1 wherein said lesion component is cholesterol and essentially all of said electromagnetic energy directed at said lesion is of a wavelength of about 248 nanometers.

6. The method of claim 5 wherein said electromagnetic energy is generated by a krypton/fluorine excimer laser and conducted to the vicinity of said lesion by at least one optical fiber.

7. The method of claim 6 wherein said optical fiber is a fused silica optical fiber having a core diameter of from about 100 microns to about 600 microns.

8. The method of claim 1 wherein said electromagnetic energy directed at said lesion is monochromatic.

9. The method of claim 8 wherein said electromagnetic energy is generated by a laser and conducted to the vicinity of said lesion by at least one optical fiber.

10. The method of claim 9 wherein said laser is an excimer laser.